Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - Lincoff, A. Michael; Brown-Frandsen, Kirstine; Colhoun, Helen M.; Deanfield, John; Emerson, Scott S.; Esbjerg, Sille; Hardt-Lindberg, Søren; Hovingh, G. Kees; Kahn, Steven E.; Kushner, Robert F.; Lingvay, Ildiko; Oral, Tugce K.; et al. (The New England journal of medicine, 2023)
Keywords: Antidiabetics; Body weight; Cardiology; Cardiology General; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Cardiovascular Agents - therapeutic use; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Cerebral infarction; Coronary Disease; Design; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Endocrinology; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor Agonists - administration & dosage; Glucagon-Like Peptide-1 Receptor Agonists - adverse effects; Glucagon-Like Peptide-1 Receptor Agonists - therapeutic use; Glucagon-Like Peptides; Glucose; Heart attacks; Heart failure; Hemoglobin; Humans; Hypoglycemic Agents; Hypotheses; Hypothesis testing; Metabolism; Myocardial Infarction; Obesity; Obesity - complications; Overweight; Overweight - complications; Patients; Placebos; Prevention; Statistical analysis; Stroke